OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Discriminating promiscuous from target‐specific autoantibodies in COVID‐19
Mikhail Lebedin, Clara Vázquez García, Lisa Spatt, et al.
European Journal of Immunology (2023) Vol. 53, Iss. 5
Open Access | Times Cited: 14
Mikhail Lebedin, Clara Vázquez García, Lisa Spatt, et al.
European Journal of Immunology (2023) Vol. 53, Iss. 5
Open Access | Times Cited: 14
Showing 14 citing articles:
Autoantibodies in COVID-19: implications for disease severity and clinical outcomes
Yannick Galipeau, Curtis Cooper, Marc‐André Langlois
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Yannick Galipeau, Curtis Cooper, Marc‐André Langlois
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Autoantibodies to ACE2 and immune molecules are associated with COVID-19 disease severity
Eric S. Geanes, Rebecca McLennan, Cas LeMaster, et al.
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 10
Eric S. Geanes, Rebecca McLennan, Cas LeMaster, et al.
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 10
Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects
Е. Л. Насонов
Rheumatology Science and Practice (2024) Vol. 62, Iss. 1, pp. 32-54
Open Access | Times Cited: 5
Е. Л. Насонов
Rheumatology Science and Practice (2024) Vol. 62, Iss. 1, pp. 32-54
Open Access | Times Cited: 5
Five Key Criteria for Identifying Optimal Therapeutic Targets in Protein‐Mediated Diseases
Mohammed Baqur S. Al‐Shuhaib, Jafar M. B. Al‐Shuhaib
ChemistrySelect (2025) Vol. 10, Iss. 4
Closed Access
Mohammed Baqur S. Al‐Shuhaib, Jafar M. B. Al‐Shuhaib
ChemistrySelect (2025) Vol. 10, Iss. 4
Closed Access
Autoantibodies targeting angiotensin‐converting enzyme 2 are prevalent and not induced by SARS ‐CoV ‐2 infection
Yannick Galipeau, Nicolas Castonguay, Pauline S. McCluskie, et al.
The FASEB Journal (2025) Vol. 39, Iss. 4
Open Access
Yannick Galipeau, Nicolas Castonguay, Pauline S. McCluskie, et al.
The FASEB Journal (2025) Vol. 39, Iss. 4
Open Access
Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses
Mikhail Lebedin, Christoph Ratswohl, Amar K. Garg, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109330-109330
Open Access | Times Cited: 2
Mikhail Lebedin, Christoph Ratswohl, Amar K. Garg, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109330-109330
Open Access | Times Cited: 2
Cellular pathways and molecular events that shape autoantibody production in COVID-19
Gregory J. Tsay, Moncef Zouali
Journal of Autoimmunity (2024) Vol. 147, pp. 103276-103276
Closed Access | Times Cited: 2
Gregory J. Tsay, Moncef Zouali
Journal of Autoimmunity (2024) Vol. 147, pp. 103276-103276
Closed Access | Times Cited: 2
COVID-19, G protein-coupled receptor, and renin-angiotensin system autoantibodies: Systematic review and meta-analysis
Abolfazl Akbari, Alireza Hadizadeh, Muhammad Islampanah, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 9, pp. 103402-103402
Closed Access | Times Cited: 7
Abolfazl Akbari, Alireza Hadizadeh, Muhammad Islampanah, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 9, pp. 103402-103402
Closed Access | Times Cited: 7
Autoantibodies against angiotensin‐converting enzyme 2 (ACE2) after COVID‐19 infection or vaccination
James Yiu-Hung Tsoi, Jian‐Piao Cai, Jianwen Situ, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 12
Open Access | Times Cited: 7
James Yiu-Hung Tsoi, Jian‐Piao Cai, Jianwen Situ, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 12
Open Access | Times Cited: 7
Autoantibodies Targeting Angiotensin Converting Enzyme 2 Are Prevalent and Not Induced by SARS-CoV-2 Infection
Yannick Galipeau, Nicolas Castonguay, Pauline S. McCluskie, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Yannick Galipeau, Nicolas Castonguay, Pauline S. McCluskie, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Novel and unique rheumatoid factors cross-react with viral epitopes in COVID-19
Maya F. Amjadi, Maxwell H. Parker, Ryan R. Adyniec, et al.
Journal of Autoimmunity (2023) Vol. 142, pp. 103132-103132
Open Access | Times Cited: 4
Maya F. Amjadi, Maxwell H. Parker, Ryan R. Adyniec, et al.
Journal of Autoimmunity (2023) Vol. 142, pp. 103132-103132
Open Access | Times Cited: 4
Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation
Savanna S. Skeeters, Kamal Bagale, Galina A. Stepanyuk, et al.
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 3, pp. 101301-101301
Closed Access
Savanna S. Skeeters, Kamal Bagale, Galina A. Stepanyuk, et al.
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 3, pp. 101301-101301
Closed Access
Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study
Mauro Mantovani, Paolo Bellavite, Sergio Fazio, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2852-2852
Open Access
Mauro Mantovani, Paolo Bellavite, Sergio Fazio, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2852-2852
Open Access
Pandemieforschung: von Autoantikörpern und Impfstoff-Innovationen
Kathrin de la Rosa
BIOspektrum (2023) Vol. 29, Iss. 6, pp. 614-616
Open Access
Kathrin de la Rosa
BIOspektrum (2023) Vol. 29, Iss. 6, pp. 614-616
Open Access
